Search | Clinical Trials Finder

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 65
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more

Conditions: Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies
Interventions: SAT-3247, Placebo; Drug
Lead sponsor: Satellos Bioscience, Inc.; Industry
Eligibility: 7 Years to 9 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more

Conditions: Wrinkle
Interventions: Restylane Silk, Saline, Optical Coherence Tomography; Drug · Device
Lead sponsor: Heidi Waldorf; Other
Eligibility: 25 Years to 55 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyponatremia With Normal Extracellular Fluid Volume, Hyponatremia With Excess Extracellular Fluid Volume
Interventions: Not listed
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 6
States / cities: Lomita, California • Clearewater, Florida • Fleming Island, Florida + 3 more

Conditions: Type 1 Diabetes, New Onset
Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 9 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: San Francisco, California • New Haven, Connecticut • Gainesville, Florida + 7 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ezogabine, Placebo; Drug
Lead sponsor: Brian Wainger; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more

Conditions: Alopecia Areata
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 41 more

Conditions: Malignant Neoplasm
Interventions: Dexamethasone, Placebo, Questionnaire, Quality-of-Life Assessment, Everolimus; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 319
States / cities: Birmingham, Alabama • Kingman, Arizona • Fort Smith, Arkansas + 198 more

Conditions: Methamphetamine-dependence
Interventions: Magnetic resonance imaging (MRI), Methamphetamine Hydrochloride Tablets, Placebo oral tablet; Behavioral · Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Healthy
Interventions: Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder
Interventions: Lurasidone 20 mg, Lurasidone 60 mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 27
States / cities: Birmingham, Alabama • Imperial, California • National City, California + 21 more

Conditions: Hyperuricemia, Gout, Qt Interval, Variation in
Interventions: LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atopic Dermatitis
Interventions: Placebo, Rilzabrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Northridge, California • Colorado Springs, Colorado • Miami, Florida + 5 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide SAR439977, Placebo, Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more

Conditions: Hypercholesterolemia
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Raleigh, North Carolina + 2 more

Conditions: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 6 more

Conditions: Acne Vulgaris
Interventions: Sarecycline, Placebo; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 9 Years to 45 Years
Enrollment: 968 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 57
States / cities: Beverly Hills, California • Encino, California • La Mesa, California + 50 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Amisodin, Placebo; Drug · Other
Lead sponsor: PRG Science & Technology Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Paget's Disease of Bone
Interventions: zoledronic acid, placebo to zoledronic acid, Risedronate, Placebo to risedronate, Calcium and vitamin D supplements; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 10
States / cities: Tucson, Arizona • Colorado Springs, Colorado • Indianapolis, Indiana + 7 more

Conditions: Major Depressive Disorder
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Huntsville, Alabama • Pico Rivera, California • Farmington, Connecticut + 21 more

Conditions: Bipolar Depression, Suicidal Ideation
Interventions: NRX-101, Lurasidone HCl, Placebo; Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Interventions: Pembrolizumab, Placebo, Cisplatin, Capecitabine, 5-fluorouracil, Docetaxel, Oxaliplatin, Leucovorin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 14
States / cities: Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more

Conditions: Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Interventions: AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 14
States / cities: Anaheim, California • Santa Rosa, California • West Hills, California + 10 more

Conditions: Fibromyalgia
Interventions: Placebo, Milnacipran; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: Not listed
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 51 more

Search by objective public record fields.

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Restylane Silk for Treatment of Chest Wrinkles

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

Effects of Genotype on Resting State Connectivity During Methamphetamine Administration

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

Major Depressive Disorder With Mixed Features

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NRX101 Glx Biomarker Validation Study

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia